INBX Rises 81% Following Study Results; FEMY, CING, CYH Surge in After-Hours Trading
Inhibrx Biosciences Surge: Inhibrx Biosciences (INBX) shares soared over 81% after positive Phase 2 trial results for ozekibart in treating advanced chondrosarcoma, alongside updates on other cancer treatment studies.
Femasys Gains: Femasys Inc. (FEMY) saw an 18% increase following the launch of a post-market clinical study for its FemBloc Permanent Birth Control, complying with EU regulations.
Cingulate's Presentation: Cingulate Inc. (CING) rose over 6% after announcing that data from its ADHD treatment candidate, CTx-1301, will be presented at the AACAP Annual Meeting, highlighting its potential in ADHD management.
Community Health Systems Performance: Community Health Systems, Inc. (CYH) shares increased over 4% after reporting positive Q3 results, contributing to a generally favorable after-hours trading environment for biotech stocks.
Trade with 70% Backtested Accuracy
Analyst Views on ASND
About ASND
About the author
FDA Approves Zycubo for Pediatric Menkes Disease Treatment
- FDA Drug Approval: On January 13, 2026, Sentynl Therapeutics' Zycubo received FDA approval as the first treatment for pediatric patients with Menkes disease, representing a significant breakthrough in the treatment of rare neurodegenerative disorders and is expected to enhance patient quality of life.
- Food Labeling Reform: On January 21, 2026, the U.S. regulator issued a Request for Information aimed at improving gluten ingredient disclosure in foods, particularly focusing on allergic reactions to rye and barley, which could drive significant changes in food industry labeling transparency.
- Future Review Outlook: As February 2026 approaches, several drugs are set for FDA review, with the industry eagerly anticipating the regulatory outcomes, as successful approvals could present substantial market opportunities for related biotech firms.
- Biotech Stock Focus: The FDA's review decisions will directly impact the performance of biotech stocks, prompting investors to closely monitor the upcoming review results to assess market dynamics and investment strategies.
Ascendis Pharma (ASND) Stock Rises 7.5% Amid Takeover Speculation
- Takeover Rumors: Ascendis Pharma (ASND) shares rose 7.5% amid speculation that a Switzerland-based pharmaceutical company and another European firm are eyeing the company, indicating market optimism about its future prospects.
- Market Capitalization: With a market cap of $13.3 billion, Ascendis Pharma reflects investor recognition of its potential acquisition value, highlighting its competitiveness in the biopharmaceutical sector.
- Investor Interest: Traders noted that a Betaville 'uncooked' alert circulated on Thursday, further igniting market interest in Ascendis, which may attract more investors to its stock.
- Financial Performance: Ascendis Pharma reported a GAAP EPS of -€1.00 and revenue of €213.63 million, and while current financial performance is weak, the takeover rumors may enhance market expectations for its future profitability.
Ascendis Pharma Updates 2026 Strategic Roadmap, Projects €683 Million Revenue
- Revenue Growth Projection: Ascendis Pharma anticipates total revenue of approximately €683 million for 2025, with YORVIPATH expected to generate €477 million and SKYTROFA €206 million, indicating strong growth potential in the biopharma sector.
- Market Expansion Plans: By the end of 2025, YORVIPATH will be commercially available in over 30 countries, with full launches in 10 additional countries expected by the end of 2026, further solidifying its global market position.
- R&D Pipeline Progress: The PDUFA goal date for TransCon CNP is set for February 28, 2026, with a marketing authorization application submitted to the EMA, anticipating a regulatory decision in Q4 2026, showcasing the company's proactive drug development efforts.
- Share Repurchase Program: The Ascendis Board has authorized a $120 million share repurchase program aimed at enhancing shareholder value based on market conditions and share price fluctuations, reflecting the company's confidence in its future financial health.
Ascendis Pharma Reports Positive Phase 2 Results for Pediatric Achondroplasia Treatment
- Clinical Trial Results: Ascendis Pharma's COACH Phase 2 trial for pediatric achondroplasia demonstrated significant annualized growth velocity increases, with treatment-naïve patients achieving 8.8 cm per year, a 3.9 cm gain from baseline, indicating the therapy's effectiveness in enhancing growth outcomes.
- Safety Profile: The combination therapy was well tolerated over the 52-week treatment period, with all patients completing the trial and no serious adverse events reported, such as symptomatic hypotension or fractures, underscoring the therapy's safety and feasibility.
- Future Research Directions: Ascendis is preparing for a pivotal Phase 3 trial to compare TransCon CNP monotherapy with the combination regimen, while also planning to integrate the combination therapy into its existing U.S. regulatory filing strategy, aiming to simplify treatment for patients and caregivers.
- Financial Position: As of the end of Q3, Ascendis reported approximately €539 million in cash and cash equivalents, ensuring funding for future clinical trials and technology expansion, further supporting its development in endocrine and rare disease indications.
Evaluating Ascendis Pharma's 2025 Valuation Following Significant Gains and DCF Growth Potential
Stock Performance Overview: Ascendis Pharma has seen a significant increase of 44.9% year-to-date, despite a recent decline of 9.3% over the past week, driven by optimism around its pipeline and regulatory progress.
Valuation Insights: A Discounted Cash Flow (DCF) analysis indicates that Ascendis Pharma is undervalued by approximately 73.3%, with an estimated intrinsic value of $748 per share compared to its current trading price.
Price to Sales Ratio: The company trades at a Price to Sales (P/S) ratio of 16.1x, which is above the industry average but aligns with its growth outlook and risk profile, suggesting the valuation is reasonable.
Dynamic Valuation Narratives: Investors can create personalized narratives that connect Ascendis Pharma's competitive position and future prospects to their fair value estimates, leading to varied opinions on the stock's worth based on individual assumptions.
Ascendis Pharma Rises on Acquisition Rumors
Takeover Speculation: Ascendis Pharma's ADRs surged 8% due to speculation about potential takeover interest, although the identity of the interested party remains unclear.
Market Capitalization: The company has a market capitalization of $11.8 billion, indicating its significant presence in the pharmaceutical industry.
FDA Approves Zycubo for Pediatric Menkes Disease Treatment
- FDA Drug Approval: On January 13, 2026, Sentynl Therapeutics' Zycubo received FDA approval as the first treatment for pediatric patients with Menkes disease, representing a significant breakthrough in the treatment of rare neurodegenerative disorders and is expected to enhance patient quality of life.
- Food Labeling Reform: On January 21, 2026, the U.S. regulator issued a Request for Information aimed at improving gluten ingredient disclosure in foods, particularly focusing on allergic reactions to rye and barley, which could drive significant changes in food industry labeling transparency.
- Future Review Outlook: As February 2026 approaches, several drugs are set for FDA review, with the industry eagerly anticipating the regulatory outcomes, as successful approvals could present substantial market opportunities for related biotech firms.
- Biotech Stock Focus: The FDA's review decisions will directly impact the performance of biotech stocks, prompting investors to closely monitor the upcoming review results to assess market dynamics and investment strategies.
Ascendis Pharma (ASND) Stock Rises 7.5% Amid Takeover Speculation
- Takeover Rumors: Ascendis Pharma (ASND) shares rose 7.5% amid speculation that a Switzerland-based pharmaceutical company and another European firm are eyeing the company, indicating market optimism about its future prospects.
- Market Capitalization: With a market cap of $13.3 billion, Ascendis Pharma reflects investor recognition of its potential acquisition value, highlighting its competitiveness in the biopharmaceutical sector.
- Investor Interest: Traders noted that a Betaville 'uncooked' alert circulated on Thursday, further igniting market interest in Ascendis, which may attract more investors to its stock.
- Financial Performance: Ascendis Pharma reported a GAAP EPS of -€1.00 and revenue of €213.63 million, and while current financial performance is weak, the takeover rumors may enhance market expectations for its future profitability.
Ascendis Pharma Updates 2026 Strategic Roadmap, Projects €683 Million Revenue
- Revenue Growth Projection: Ascendis Pharma anticipates total revenue of approximately €683 million for 2025, with YORVIPATH expected to generate €477 million and SKYTROFA €206 million, indicating strong growth potential in the biopharma sector.
- Market Expansion Plans: By the end of 2025, YORVIPATH will be commercially available in over 30 countries, with full launches in 10 additional countries expected by the end of 2026, further solidifying its global market position.
- R&D Pipeline Progress: The PDUFA goal date for TransCon CNP is set for February 28, 2026, with a marketing authorization application submitted to the EMA, anticipating a regulatory decision in Q4 2026, showcasing the company's proactive drug development efforts.
- Share Repurchase Program: The Ascendis Board has authorized a $120 million share repurchase program aimed at enhancing shareholder value based on market conditions and share price fluctuations, reflecting the company's confidence in its future financial health.
Ascendis Pharma Reports Positive Phase 2 Results for Pediatric Achondroplasia Treatment
- Clinical Trial Results: Ascendis Pharma's COACH Phase 2 trial for pediatric achondroplasia demonstrated significant annualized growth velocity increases, with treatment-naïve patients achieving 8.8 cm per year, a 3.9 cm gain from baseline, indicating the therapy's effectiveness in enhancing growth outcomes.
- Safety Profile: The combination therapy was well tolerated over the 52-week treatment period, with all patients completing the trial and no serious adverse events reported, such as symptomatic hypotension or fractures, underscoring the therapy's safety and feasibility.
- Future Research Directions: Ascendis is preparing for a pivotal Phase 3 trial to compare TransCon CNP monotherapy with the combination regimen, while also planning to integrate the combination therapy into its existing U.S. regulatory filing strategy, aiming to simplify treatment for patients and caregivers.
- Financial Position: As of the end of Q3, Ascendis reported approximately €539 million in cash and cash equivalents, ensuring funding for future clinical trials and technology expansion, further supporting its development in endocrine and rare disease indications.
Evaluating Ascendis Pharma's 2025 Valuation Following Significant Gains and DCF Growth Potential
Stock Performance Overview: Ascendis Pharma has seen a significant increase of 44.9% year-to-date, despite a recent decline of 9.3% over the past week, driven by optimism around its pipeline and regulatory progress.
Valuation Insights: A Discounted Cash Flow (DCF) analysis indicates that Ascendis Pharma is undervalued by approximately 73.3%, with an estimated intrinsic value of $748 per share compared to its current trading price.
Price to Sales Ratio: The company trades at a Price to Sales (P/S) ratio of 16.1x, which is above the industry average but aligns with its growth outlook and risk profile, suggesting the valuation is reasonable.
Dynamic Valuation Narratives: Investors can create personalized narratives that connect Ascendis Pharma's competitive position and future prospects to their fair value estimates, leading to varied opinions on the stock's worth based on individual assumptions.
Ascendis Pharma Rises on Acquisition Rumors
Takeover Speculation: Ascendis Pharma's ADRs surged 8% due to speculation about potential takeover interest, although the identity of the interested party remains unclear.
Market Capitalization: The company has a market capitalization of $11.8 billion, indicating its significant presence in the pharmaceutical industry.
